iTolerance, Inc.
Clinical Development of iTol-102, Allogenic Stem Cell Derived Islet Cells without Chronic Immunosuppression to cure Type 1 Diabetes — US partner. Israeli partner: Kadimastem Ltd. (Ness Ziona (Central Israel)). Sector: Life Sciences, Pharma/Cell Therapy.